Liminatus Pharma Executes 1-for-50 Reverse Split to Preserve Nasdaq Listing
The clinical-stage biopharmaceutical company will consolidate roughly 67.2 million shares into about 1.3 million to meet exchange requirements.
Liminatus Pharma (LIMN), a clinical-stage biopharmaceutical company, announced a 1-for-50 reverse stock split designed to bring its share price back into compliance with Nasdaq's minimum listing standards. The consolidation takes effect August 20, 2026.
The split will reduce Liminatus's outstanding share count from 67,160,362 to approximately 1,343,208. For shareholders, the arithmetic is straightforward: every 50 shares held will convert into one share, with the per-share price rising proportionally. The company's overall market capitalization remains unchanged at the moment of the split.
Reverse splits carry no inherent signal about a company's operating trajectory, but they do indicate that the stock had fallen below the $1 minimum bid price that Nasdaq requires for continued listing. By consolidating at a 50-to-1 ratio, Liminatus is attempting to clear that threshold with enough margin to avoid a repeat in the near term.
The move places Liminatus among a cohort of small-cap biotechnology companies that have turned to reverse splits as clinical programs consume cash and share prices drift lower. The consolidation does not alter the company's pipeline, balance sheet, or cash position; it reshapes the equity structure to satisfy an exchange rule.
Investors will watch whether the post-split share price holds above the $1 floor in the weeks ahead. A sustained move below that level could trigger a new compliance notice from the exchange, potentially forcing additional corporate action.
Sources: Liminatus Pharma press release, Aug. 18, 2026.